Sorafenib is the only approved targeted drug for hepatocellular carcinoma (HCC), but its effect on patients' survival gain is limited and varies over a wide range depending on pathogenetic conditions. Thus, enhancing the efficacy of sorafenib and finding a reliable predictive biomarker are crucial to achieve efficient control of HCCs. In this study, we utilized a systems approach by combining transcriptome analysis of the mRNA changes in HCC cell lines in response to sorafenib with network analysis to investigate the action and resistance mechanism of sorafenib. Gene list functional enrichment analysis and gene set enrichment analysis revealed that proteotoxic stress and apoptosis modules are activated in the presence of sorafenib. Further analysis of the endoplasmic reticulum stress network model, combined with in vitro experiments, showed that introducing an additional stress by treating the orally active protein disulfide isomerase (PDI) inhibitor (PACMA 31) can synergistically increase the efficacy of sorafenib in vitro and in vivo, which was confirmed using a mouse xenograft model. We also found that HCC patients with high PDI expression show resistance to sorafenib and poor clinical outcomes, compared to the low-PDI-expression group. Conclusion: These results suggest that PDI is a promising therapeutic target for enhancing the efficacy of sorafenib and can also be a biomarker for predicting sorafenib responsiveness. (HEPATOLOGY 2017;66:855-868). S orafenib, the first oral multikinase inhibitor, was approved for the treatment of hepatocellular carcinoma (HCC) a few years ago, but it has shown limited efficacy. Only a small fraction of patients (around 10%) show a clinical response to sorafenib, and, at most, 30%-40% of HCC patients demonstrate a disease control rate.
S orafenib, the first oral multikinase inhibitor, was approved for the treatment of hepatocellular carcinoma (HCC) a few years ago, but it has shown limited efficacy. Only a small fraction of patients (around 10%) show a clinical response to sorafenib, and, at most, 30%-40% of HCC patients demonstrate a disease control rate. (1) In the SHARP trial, the median survival period was prolonged by sorafenib up to 3 months, but its benefit is not enough considering its high price and varying efficacy depending on patients. (2) In general, a targeted anticancer drug should have a biomarker to predict its clinical response. Single kinase inhibitors, such as tarceva (epidermal growth factor receptor [EGFR] inhibitor) or crizotinib (anaplastic lymphoma kinase [ALK] inhibitor), have as predictive markers EGFR mutation and ALK translocation, respectively. However, such markers are still not available for sorafenib because it targets multiple kinases, including v-Raf murine sarcoma viral oncogene homolog B1, vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor, FMS-like tyrosine kinase-3, rearranged during transfection, and cellular homolog of the feline sarcoma viral oncogene v-kit, complicating the mechanism of action. (3) Thus, it is clinically important to investigate the mechanism of resistance to sorafenib and develop a new therapeutic strategy that can improve the efficacy of sorafenib.
To discover the action and resistance mechanism of sorafenib, we adopted systems approaches as follows: First, we analyzed mRNA expression changes in HCC cell lines in response to sorafenib and inferred that the endoplasmic reticulum (ER) stress pathway contributes to apoptosis driven by sorafenib. Second, based on these pathways, we constructed a network model and identified an apoptosis-promoting module as well as antiapoptotic modules upon sorafenib treatment. Then, using the network kernel analysis and in silico simulation based on the logic diagram and a computational model, we found that protein disulfide isomerase (PDI) can be a therapeutic target for enhancing the efficacy of sorafenib.
We further established that the combinatorial treatment of sorafenib and PDI inhibitor shows a synergistic effect in vitro and in vivo. In addition, we found that high PDI expression correlates with a poor response rate to sorafenib treatment and adverse clinical outcomes in the HCC patient cohort.
Taken together, these results suggest that PDI can be not only a useful predictive biomarker for sorafenib, but also a promising target for a combination therapy to overcome the resistance to sorafenib.
Materials and Methods

mRNA MICROARRAY EXPERIMENTS AND ANALYSIS
mRNA microarray experiments were performed in triplicate. HCC cell lines (SNU761, Huh7, Hep3B, and HepG2) were treated with sorafenib 3 lM for 24 hours, whereas the control group was treated with only dimethyl sulfoxide (DMSO). Experiments were performed as described in the Supporting Information.
Dulbecco's modified Eagle's medium (WelGENE Inc., Gyeongsan-si, Republic of Korea) with 10% fetal bovine serum and antibiotics (100 units/mL of penicillin, 100 ug/mL of streptomycin, and 0.25 lg/mL of Fungizone; Life Technologies Corp., Carlsbad, CA) at 378C in a humidified atmosphere containing 5% CO 2 .
REAGENTS
Sorafenib tosylate was purchased from LC Laboratories (Woburn, MA). DMSO, thapsigargin, and propidium iodide (PI) were purchased from SigmaAldrich (St Louis, MO). PACMA 31 was purchased from Tocris Bioscience (Bristol, UK). Bortezomib was purchased from Selleck Chemicals (MA).
WESTERN BLOTTING ANALYSIS
Cells were lysed in lysis buffer (20 mM of HEPES [pH 7.2], 150 mM of NaCl, 0.5% Triton X-100, 10% glycerol, 1 lg/mL of aprotinin, 1 lg of leupeptin, 1 mM of Na 3 VO 4 , and 1 mM of NaF). Cell lysates were centrifuged at 13,000 rpm for 15 minutes at 48C, and the resulting supernatants followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting analysis. For immunoblotting, anti-phospho-elF2a (eukaryotic initiation factor 2 alpha; Cell Signaling Technology, Danvers, MA), anti-PDI (Invitrogen, Carlsbad, CA), and anti-aactinin (Santa Cruz Biotechnology, Inc., Dallas, TX) were used. The rabbit polyclonal anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase) antibody was a generous gift from Dr. Ki-Sun Kwon (Korea Research Institute of Bioscience and Biotechnology). 
RT-PCR AND qRT-PCR
PATHWAY-FOCUSED GENE EXPRESSION PROFILING (PCR-BASED ARRAY)
Pathway-focused gene expression profiling was done using a 96-well human unfolded protein response (UPR) PCR Array, RT 2 Profiler PCR array (PAHS-089Z, Human UPR RT 2 Profiler PCR Array; Qiagen, Hilden, Germany). In this array, 84 wells contained all the components required for the PCR reaction in addition to a primer for a single gene in each well. These genes are involved in unfolded protein binding, ER protein folding quality control, regulation of cholesterol metabolism, regulation of translation, ERassociated degradation (ERAD), ubiquitination, transcription factors, protein folding, protein disulfide isomerization, heat shock proteins, and apoptosis. A diluted cDNA template was mixed with the RT 2 SYBR green master mix (Qiagen), according to the manufacturer's protocol, and loaded onto the 96-well array plate. qPCR analysis was performed using the QuantStudio 5 (Applied Biosystems), by heating the plate to 958C for 10 minutes, followed by 40 cycles of 958C for 15 seconds and 608C for 1 minute. The data were normalized, across all plates, to the following housekeeping genes: hypoxanthine phosphoribosyltransferase 1; beta-2-microglobulin, ribosomal protein, large, P0 (RPLP0); GAPDH; and b-actin.
PLASMID CONSTRUCTION, VIRUS PRODUCTION, AND INFECTION
For lentivirus production, HEK 293T cells were transfected with relevant lentiviral plasmid and packaging mix (pLP1, pLP2, and pLP/VSVG) using Lipofectamine (Invitrogen), according to the manufacturer's instructions. For overexpression experiments, the full-length cDNA of PDI was amplified by RT-PCR from total RNA isolated from SNU761 cells using PCR amplification with a forward primer containing 
NETWORK KERNEL ANALYSIS
To investigate the core structure of a network, the kernel identification algorithm, which condenses a biological network into a smaller one while preserving the input-output dynamics of a network and topological aspects, was adopted as described. (4) This algorithm recursively replaces the neighborhood subnetwork of each node with a smaller network, which has the same dynamics as the original network, until no further replacement is possible. It is known that essential genes, disease-associated genes, and drug targets are enriched in the reduced kernel network. 
THE LOGIC DIAGRAM AND COMPUTATIONAL MODELING OF ER STRESS PATHWAY
An ordinary differential equation (ODE)-based computational model was constructed to investigate the effect of combination treatments. We have applied the step function (h) to describe the dynamic activities by logical approximation of ODE.
Step function is defined as follows.
where T is the threshold for the node activation. 
CELL VIABILITY ASSAYS
HCC cells were seeded into 96-well plate at a density of 6 3 10 3 cells/well in growth medium, incubated for 24 or 48 hours, and then treated with the indicated concentrations of sorafenib (LC Laboratories) and PACMA 31 (Tocris Bioscience), alone or in combination. Following incubation of the plates for 24 hours, relative cell viability was measured. Briefly, WST-1 solution (Daeillab, Republic of Korea) was added to cells for 30 minutes 2 hours and then measured the absorbance at 450 nm using a xMark Microplate Absorbance Spectrophotometer (Bio-Rad, Hercules, CA).
CELL DEATH ASSAY
To analyze cell death, PI-based assays were performed. IncuCyte ZOOM (Essen Biosciences, Ann Arbor, MI) was used to detect cell death according to the manufacturer's instructions. HCC cells were seeded into a 96-well plate and cultured for 24 hours (6 3 10 3 cells/well). Cells were then treated with the indicated concentrations of sorafenib (LC Laboratories) and PACMA 31 (Tocris Bioscience), alone or in combination for 24 hours. After seeding, cells were imaged using IncuCyte ZOOM (Essen Bioscience). To assess cell death, average areas of PI-labeled cells were determined at each time point using the IncuCyte ZOOM analysis software. Images were captured at 3-hour intervals from three separate regions per well with a 203 objective. ; and (6) serum total bilirubin <3.0 mg/dL, serum transaminases <200 IU/L, and serum creatinine < 1.5 mg/dL. These eligibility criteria were based on the vulnerability to adverse side effects. Diagnosis of HCC was confirmed based on hematoxylin-eosin staining of histopathological specimens in all patients. Sorafenib was given orally at a dose of 400 mg twice-daily. Treatment interruptions and up to two dose reductions (first to 400 mg once-daily and then to 400 mg every 2 days) were permitted for drug-related adverse effects (the Common Terminology Criteria for Adverse Events [version 3]). (5) Treatment was continued until the radiological progression, as defined by the modified Response Evaluation Criteria in Solid Tumors (mRECIST). (6) Assessed by contrast-enhanced computed tomography or magnetic resonance imaging every 6-8 weeks, therapeutic response to sorafenib was defined according to the criteria of mRECIST. Complete response (CR) was defined as disappearance of all arterial-enhancing lesions. Partial response (PR) was defined as at least a 30% decrease in the sum of the longest diameter of viable target lesions, taking as reference the baseline sum of the diameters of target lesions. Progressive disease (PD) was defined as at least 20% increase in the sum of the diameters of viable target lesions, taking as reference the smallest sum of the diameters of viable target lesions recorded since treatment started. Stable disease (SD) was defined as any cases that do not meet either PR or PD. When the response achieved for intrahepatic HCC differed from that for extrahepatic HCC, the worse response was determined as the achieved response. Assessment of response was introduced best overall response of mRECIST across all assessment time points.
ANIMALS AND TREATMENTS
IMMUNOHISTOCHEMICAL ANALYSIS
Anti-PDI antibody (clone RL90) for immunohistochemistry (IHC) was purchased from Abcam (Cambridge, UK), and immunostaining was done using the Ventana Optiview system (Roche Diagnositics, Mannheim, Germany). Slides were scanned by Aperio ScanScope CS2 (Leica Biosystems, Nussloch, Germany), and image files of each core were obtained. PDI immunopositivity was calculated by the Positive Pixel Count Algorithm of the Aperio ImageScope (Leica Biosystems). Two or more cores per case were examined, and the highest value was used as a representative value.
STATISTICAL ANALYSIS
The Mann-Whitney U test and the Kruskal-Wallis test were used to analyze differences between the different groups. The chi-square test and Fisher's exact test were used for categorical data. To define the best cut-off value for predicting outcome, time-dependent receiver-operating characteristic (ROC) curves for censored survival data were constructed. (7) The best cutoff value was adopted when it had the maximal sum of sensitivity and specificity. Time to progression (TTP) was calculated from the first day of sorafenib to PD. Overall survival (OS) was calculated from the date of commencement of sorafenib to the date of death or last contact. Conventional clinical factors at the time of entry into the study and immunopositivity for PDI were analyzed to identify variables that influenced survival as determined by the Kaplan-Meier method and compared by the log-rank test.
Step-wise, multivariate analysis was performed using the Cox proportional hazards model to identify independent variables that influenced survival. Factors found to be significantly related to outcome by univariate analysis were included in the multivariate analysis. All statistical analyses were performed using SPSS software (version 19.0; SPSS, Inc., Chicago, IL), and P values of <0.05 were considered significant.
Results
SORAFENIB-RESPONSIVE mRNA CHANGES INDICATE THAT APOPTOSIS CAN BE INDUCED BY PROTEOTOXIC STRESS FROM SORAFENIB
To identify the action mechanism and the resistance mechanism of sorafenib, the transcriptomic changes of HCC cell lines (SNU761, Huh7, Hep3B, and HepG2) before and after sorafenib treatment were analyzed. Although their sensitivity to sorafenib was generally similar, SNU761 and Huh7 cells were relatively resistant to sorafenib compared to Hep3B and HepG2 cells (Supporting Fig. S1 ). To find out biologically relevant gene sets that significantly change, gene list functional enrichment analysis and gene set enrichment analysis were done (Supporting Materials and Methods).
It was shown that the UPR gene set was significantly changed in SNU761, Huh7, and Hep3B, but to a lesser degree in HepG2 (Supporting Files S1 and S2). This result raises the possibility that sorafenib causes proteotoxic stress, which may lead to apoptosis or resistance in some groups of HCC cell lines.
To confirm this hypothesis, western blotting for phospho-elF2a, which is a marker of protein kinase RNA-like endoplasmic reticulum kinase (PERK) axis activation, crucial in UPR, was conducted and it was shown that sorafenib induces UPR. In addition, RT-PCR of CHOP (DNA-damage-inducible transcript 3), which is known to be a marker for ER stressinduced apoptosis, suggests that ER stress-induced apoptosis might be brought about by sorafenib (Fig.  1) . To confirm that hypothesis, cell viability assays of Hep3B cells expressing scrambled shRNA or CHOP shRNA were performed. Sorafenib-induced apoptosis was reduced in CHOP knockdown cells compared to control cells (Supporting Fig. S2 ).
THE EFFECT OF SORAFENIB ON ER STRESS NETWORK
To clarify the effect of sorafenib on ER stress pathway and identify molecules that can mitigate the efficacy of sorafenib and cause resistance to apoptosis, we constructed a signaling network model of ER stress (Supporting Fig. S3 ). This network model is composed of three parts. One is the UPR part that is composed of UPR signal transducers being activated by the accumulation of unfolded or misfolded protein. The others are the protein refolding part and the ERAD part that relieve the proteotoxic stress by refolding or degrading misfolded proteins, which results in cell survival.
To explore this network, a qRT-PCR-based array for 84 key molecules constituting this pathway was performed in SNU761 cell lines ( Fig. 2 ; Supporting Table S1 ). Thirty-seven of 84 molecules were significantly upregulated when sorafenib was treated, whereas none was down-regulated (Supporting Table S1 ). When these changes were displayed on the network model, both the UPR and ERAD parts were found to be activated (Supporting Fig. S3 ). Molecules for ER protein folding (Fig.  2C ) and ubiquitin-proteasome pathway (Fig. 2D,E) were up-regulated, which results in resistance to apoptotic effects of sorafenib. To test whether this phenomenon occurs in another cell line, the same experiment was performed in HepG2 and Huh7 cell lines. The HepG2 cell line was chosen because it showed a weaker UPR than other cell lines from microarray experiments, whereas the Huh7 cell line showed similar responses with the SNU761 cell line. UPRs were not apparent in the HepG2 cell line (Supporting Fig. S4 ). But the Huh7 cell line showed similar reactions with the SNU761 cell line in qRT-PCR analysis (Supporting Fig. S5 ). These results suggest that ER stress is induced depending on cellular contexts.
DISCOVERY OF A TARGET MOLECULE FOR INCREASING THE EFFICACY OF SORAFENIB
To identify candidates for the combination therapy with sorafenib, two different approaches were used. First, we applied the kernel identification algorithm, which elucidates essential nodes for network dynamics. The input set is the ER stress pathway network that consists of 20 nodes and 34 links (Supporting Fig. S6A ). By the kernel identification algorithm, it was condensed into the smaller network with six nodes and 10 links (Supporting Fig. S6B ). In this condensed network, heat shock proteins (HSPs) and PDI are found to be the crucial nodes against apoptosis. Because HSPs are the family of several molecules that cannot be completely blocked by one inhibitor, whereas PDI inhibitor can hinder the enzymatic activities of the broad ranges of the PDI family, PDI was given the first priority as a target molecule.
Second, because inhibition of proteasome by an inhibitor, such as bortezomib, has been known to cause proteotoxic stress and show synergistic effects with sorafenib, (8) the comparison between the effect of proteasome inhibitor and that of PDI inhibitor was conducted in silico and in vitro. An ordinary differential equation model based on the logical approximation was constructed and the effect of each inhibitor was simulated (Fig. 3) . PDI inhibition showed much more synergy than proteasome inhibition (Fig. 3B) , and similar results were obtained with diverse coefficient values (Supporting Fig. S7 ).
To confirm those in silico results, cell viability assay and apoptosis assay were performed in multiple cell lines (Fig. 4) . Whereas bortezomib demonstrated the mild additive effect with sorafenib (Supporting Fig.  S8 ), PACMA 31 revealed the synergistic effects.
THE EFFECT OF COMBINED TREATMENT WITH PACMA 31 ON ER STRESS NETWORK
A qRT-PCR-based array for 84 key molecules constituting ER stress network was performed (Fig. 5) . Whereas molecules intensifying apoptosis were upregulated in the combination group (Fig. 5A,B) , antiapoptotic molecules, such as X-box binding protein (XBP1) and mesencephalic astrocyte-derived neurotrophic factor (MANF), were down-regulated, even in comparison to the control group. Molecules participating in protein folding and ERAD were down-regulated in the combination treatment group compared to the sorafenib group (Fig. 5C-F network model, we found that the ERAD part (right) and protein refolding (center) were turned off whereas the apoptotic pathway was activated in the UPR part (Supporting Fig. S9 ).
In the case of HepG2, UPR was not evident upon sorafenib treatment (Supporting Fig. S4 ), but synergistic cytotoxicity was observed with PACMA 31 like other cell lines (Fig. 4) . It was shown that c-Jun N- Molecules involved in retrotranslocation (*P < 0.05). Abbreviations: AMFR, autocrine motility factor receptor; ATF, activating transcription factor 4; BAX, BCL2-associated X, apoptosis regulator; CANX, calnexin; CREB3, cAMP-responsive element-binding protein 3; DERL, derlin; DNAJC4, DnaJ heat shock protein family (Hsp40) member C4; EDEM1, ER degradation enhancing alphamannosidase like protein 1; FBXO6, F-box only protein 6; HERPUD1, homocysteine inducible ER protein with ubiquitin like domain 1; IRE1a, inositol-requiring enzyme 1 alpha; NPLOC4, NPL4 homolog, ubiquitin recognition factor; OS9, osteosarcoma amplified 9, endoplasmic reticulum lectin; PDIA, protein disulfide isomerase family A; PFDN, prefoldin; PPIA, peptidylprolyl isomerase A; RNF5, ring finger protein 5; SEC63, SEC63 Homolog, protein translocation regulator; SEL1L, SEL1L ERAD E3 Ligase Adaptor Subunit; SERP1, stress associated endoplasmic reticulum protein 1; SYVN1, synoviolin 1; TOR1A, torsin family 1 member A; UBE2J2, ubiquitin conjugating enzyme E2 J2; UBXN4, UBX domain protein 4; USP14, ubiquitin specific peptidase 14. Molecules involved in retrotranslocation (*P < 0.05). Abbreviations: AMFR, autocrine motility factor receptor; ATF6B, activating transcription factor 6B; DNAJC4, DnaJ heat shock protein family (Hsp40) member C4; EDEM1, ER degradation enhancing alpha-mannosidase like protein 1; ERN1, endoplasmic reticulum to nucleus signaling 1; GANAB, glucosidase II alpha subunit; GANC, glucosidase alpha, neutral C; HERPUD1, homocysteine inducible ER protein with ubiquitin like domain 1; HSPA1B, heat shock protein family A (Hsp70) member 1B; IRE1, inositol-requiring enzyme 1; NPLOC4, NPL4 homolog, ubiquitin recognition factor; OS9, osteosarcoma amplified 9, endoplasmic reticulum lectin; PPIA, peptidylprolyl isomerase A; PPKCSH, glucosidase-II; PPP1R15A, protein phosphatase 1 regulatory subunit 15A; RNF5, ring finger protein 5; SEC63, SEC63 Homolog, protein translocation regulator; SIL1, SIL1 nucleotide exchange factor; SYVN1, synoviolin 1; TOR1A, torsin family 1 member A; UBE2G2, ubiquitin conjugating enzyme E2 G2; VCP, valosin-containing protein.
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terminal kinase (JNK) and CHOP are induced by the combinatorial treatment of sorafenib and PACMA 31 (Supporting Fig. S10 ).
THE EFFICACY OF THE COMBINED TREATMENT WITH PACMA 31 IN VIVO
We further evaluated the effect of the combined treatment with PDI inhibitor using a xenograft mice model. The combined treatment significantly reduced tumor volume, whereas the others did not in comparison with the control group ( Fig. 6 ; two-way repeatedmeasure analysis of variance, P < 0.05).
HIGH PDI EXPRESSION CAN PREDICT A POOR CLINICAL OUTCOME AFTER SORAFENIB TREATMENT IN PATIENTS WITH HCC
To find out the relationship between PDI expression and clinical outcome in HCC patients receiving sorafenib, we analyzed PDI immunopositivity in HCC patients who have been treated with sorafenib. IHC analysis for PDI protein expression in our HCC patient cohort (n 5 95) demonstrated that PDI expression was increased in tumor tissue of 59 cases (62.1%), whereas 36 (37.9%) showed the decrease of PDI expression compared to adjacent nontumor tissue (Supporting Table S2 ). Among them, CR and PR were achieved in 2 of 95 (2.1%) and 1 of 95 (1.1%) of cases, respectively. SD was noted in 8 of 95 patients (8.4%) and disease control (CR1PR1SD) was achieved in 11 of 95 (11.6%). PD was noted in 84 of 95 (88.4%) cases. The low-PDI-expression group showed a significantly better response (disease control) to sorafenib compared to the high-PDI-expression group (22.2% vs. 5.1%, respectively; P 5 0.018; Table 1 ). These results suggest that PDI might be involved in the response to sorafenib.
We then performed survival analysis. Median TTP was 2.2 months (range, 0.1-38.7). Cumulative progressionfree survival rates at 3, 6, and 12 months were 40.8%, 19.7%, and 6.6%, respectively. Forty-seven patients were alive at the end of the observation period, whereas 47 had died. Median survival time was 10.0 months (range, 1.0-76.0). Cumulative survival rate at 3, 6, and 12 months was 85.4%, 63.5%, and 37.9%, respectively.
The impact of PDI expression in HCC tissues on the prognosis of patients treated with sorafenib was examined. The Kaplan-Meier method demonstrated significant prolongation of TTP in the low-PDIexpression group, compared to the high-PDIexpression group ( Table S4 ).
Discussion
In this study, the gene expression changes upon sorafenib treatment were analyzed and it was found that proteotoxic stress and UPR are mainly associated with the resistance mechanism of sorafenib. Moreover, in vitro study showed that sorafenib brings about ER stress-induced apoptosis, but its effect was attenuated by activation of protein refolding and ERAD pathway. Network analysis and in silico simulation to discover a target molecule that can block those compensatory responses revealed that PDI can be a candidate. Furthermore, in vitro and in vivo experiments proved that PDI inhibition shows the synergistic effect with sorafenib. We also found that PDI expression in HCC patients predicts resistance to sorafenib treatment.
PDI is one of the most abundant soluble proteins in the ER and acts as a reductase, an oxidase, and an isomerase as well as a molecular chaperone. (9) UPR is an important mechanism to sustain homeostasis between cell survival and apoptosis resulting from misfolded proteins. (10, 11) Given that PDI exerts key functions in protein folding, refolding, and even retrotranslocation for ERAD, (12) blocking this activity can be a way to hinder the mitigation of ER stress, which leads to cell death. (13) Recent studies showed that PDI plays a crucial role in cancer survival and progression. (14) (15) (16) In addition, it was reported that PDI mediates resistance to cytotoxic chemotherapy. (17) In our previous work, expression of PDI was increased in HCC compared to nontumor tissue and high PDI expression level in HCC tissue adversely affected clinical outcomes in HCC patients. (18) The results of this study suggest that PDI exerts an important role in resistance to sorafenib. But when we performed PDI overexpression experiments in in vitro, it seemed that PDI overexpression had little correlation with response to sorafenib, but appeared to make HCC cells more sensitive to the combination treatment of sorafenib and PDI inhibitor (Supporting Fig. S11 ). In addition to the low dosage of sorafenib in our study, some overexpression may not significantly affect the overall activity of PDI in in vitro, depending on cellular context, given that PDI is an enzyme. In some cell lines, it has been shown that overexpression of PDI abrogated the effect of chemotherapeutic agents. (17, 19) Maybe its effect will be diverse depending on drug dosage, cell types, and cellular context. However, in vivo, sorafenib has been known to induce tumor hypoxia through an antiangiogenic effect, (20) which leads to more exposure to ER stress that is difficult to cope with. (21) In this case, PDI overexpression can be helpful for cancer cells to survive. Indeed, in our patient cohort, high PDI expression in HCC tissues is significantly correlated with sorafenib resistance and predicts poor clinical outcomes after sorafenib treatment.
Cancer cells have developed several ways to compensate for stressful conditions. (22) If we exploit those attributes, it will be possible to increase the vulnerability of cancer to anticancer drugs. (19) In this study, we found that PDI can be a useful target.
In the course of searching a proper target molecule, we used two approaches: network kernel analysis and in silico simulations. First, network kernel analysis reduces the complex network to a simpler network while maintaining the original dynamics. (4) Given that it has been known that the remaining genes in such a reduced network are enriched with drug targets and the synthetic lethal pairs, the reduced kernel network can be useful in searching for a potential target. Second, because it has been known that in silico simulations based on ODE modeling can be useful in the quantitative analysis of the effect of targeted inhibitor, (23) we predicted that PDI inhibition can be more effective than proteasome inhibition from the simulation analysis. This might be because PDI is a hub node connecting the UPR part, protein refolding part, and ERAD part. It should be noted that PDI plays multiple roles, including the thiol-disulfide oxidoreductase, disulfide isomerase, and molecular chaperone. (24) In the qRT-PCR experiment for ER stress network, some questions can be raised. Sorafenib increases overall expression of molecules belonging to the UPR signal tranducer, chaperones, and ERAD system in SNU761 and Huh7 cells. But when combined with PDI inhibitor, a majority of chaperones and ERAD proteins are down-regulated together with antiapoptotic molecules including XBP1 and MANF. The reason why such transcriptional effects occur remains as a challenging issue. In our opinion, those expression changes might have been originated from CHOP induction by the combinatorial effect of sorafenib and PDI inhibition through uncompensated ER stress. Unfolded or misfolded client proteins can impose such ER stress, which leads to cell death in pathological conditions. The transcription factor, CHOP, is activated by ER stress, and CHOP directly activates growth arrest and DNA damage-inducible protein 34 (GADD34), which promotes ER client protein biosynthesis, but not ERAD or UPR proteins. (25) Given that endogenous reference genes of qRT-PCR analysis could be also included in the ER client proteins and might be induced by CHOP, it appears that UPR proteins, including ERAD molecules, seem to be relatively less expressed. It should be unveiled, in future studies, whether this phenomenon is caused by indirect effect through the uncompensated ER stress or the combination treatment directly regulates these molecules by other pathways. In the case of HepG2 cells, sorafenib alone seems to cause cell death in other ways without going through ER stress. However, when combined with PDI inhibitor, expression of JNK and CHOP is highly increased (Supporting Fig. S10 ). Given that JNK is also a well-known inducer of ER stress-induced apoptosis, (26) it seems that the combination treatment enhances apoptosis in HepG2 cells through the JNK-BCL2 (B-cell lymphoma 2) axis, unlike other cell lines. Further detailed mechanisms should be clarified in future studies.
In our patient cohort, PDI expression predicts resistance to sorafenib and is significantly correlated with OS and TTP after sorafenib treatment. To verify this result, additional studies are needed using other patient cohorts and the relationship with other known resistance factors, such as hypoxia-inducible factor 1 alpha and VEGFR, should be investigated. (27, 28) And, testing a patient-derived xenograft model may be a valuable method to confirm the efficacy of the combination treatment with PDI inhibitor.
In conclusion, PDI is an effective target for overcoming resistance to sorafenib treatment and can also be a predictive marker to predict sorafenib responsiveness and clinical outcomes.
